Supply Chain

152+ Pharma Supply Chain Statistics (2026)

152+ verified pharma supply chain statistics on drug shortages, cold chain losses, API sourcing, counterfeits, AI adoption and emissions, each linked to its source.

Written by Richard Gargan · Head of Growth

For supply chain consultancies

Are you a supply chain consultancy with pharma clients?

Contact UsExplore Supply Planning

The global pharmaceutical supply chain faces severe strain, marked by a record 323 active U.S. drug shortages in 2024 and $35 billion lost annually to cold chain failures. This database of 152+ verified statistics provides healthcare leaders and planning teams with critical benchmarks on sourcing risks, digital transformation, and logistics efficiency.

Key Pharma Supply Chain Statistics

These primary benchmarks highlight the mounting financial losses and operational strains across the global distribution network.

  • Active drug shortages in the United States reached an all-time high of 323 in the first quarter of 2024. (ASHP 2024[1])
  • The United States relies on foreign nations for 75 percent of its essential drug supply. (Senate Special Committee on Aging[2])
  • The global trade in counterfeit pharmaceuticals is estimated to be worth between $200 billion and $431 billion annually. (World Health Organization 2017[3])
  • More than 85% of biologics require temperature-controlled manufacturing, storage, and distribution. (Supply Chain Management Review[4])
  • Supply chains account for about 75% of emissions for public biotech and pharma companies in 2025. (My Green Lab 2025[5])
  • An estimated $35 billion is lost annually due to global pharmaceutical cold chain breakdowns. (Envirotainer[6])
  • In a 2023 survey, 99% of hospital pharmacists reported experiencing drug shortages. (ASHP 2023[1])
  • Over 50% of medicines purchased from online pharmacies are estimated to be counterfeit by the World Health Organization. (World Health Organization[7])
  • Wholesale distributors reported transaction data accuracy exceeding 98% leading up to the August 2025 DSCSA enforcement deadline. (Healthcare Distribution Alliance 2025[8])
  • The FDA attributes more than 60% of drug shortages to manufacturing quality problems. (FDA 2025[9])

Global Market and Industry Growth Statistics

Aerial view of a modern pharmaceutical distribution centre with solar-panelled roofs, loading bays and a fleet of trucks beside a motorway
The global healthcare supply chain management market was worth USD 3.9 billion in 2025 and is projected to reach USD 7.2 billion by 2035.

The global healthcare logistics market is expanding rapidly as organizations replace legacy spreadsheets with modern supply chain planning software.

  • The global pharmaceutical product market size reached more than 1 trillion U.S. dollars in 2023. (IBEF 2023[10])
  • The global healthcare supply chain management market size was valued at USD 3.9 Billion in 2025. (Market Research Future 2025[11])
  • The global healthcare supply chain management market is projected to grow to USD 7.2 Billion by 2035. (Market Research Future 2026[11])
  • The global healthcare supply chain management market is projected to grow at a CAGR of 6.33% from 2026 to 2035. (Market Research Future 2026[11])
  • The global pharmaceutical supply chain management market was valued at $2302.87 million in 2022. (Inkwood Research 2023[12])
  • The global pharmaceutical supply chain management market is expected to reach $5289.53 million by 2032. (Inkwood Research 2023[12])
  • The global pharmaceutical supply chain management market is expected to grow at a CAGR of 8.84% during the forecast period from 2023 to 2032. (Inkwood Research 2023[12])
  • Over 30 million tonnes of pharmaceutical products are consumed globally per year. (Kumar et al. 2023[13])

Cold Chain and Temperature-Controlled Logistics Statistics

Interior of a temperature-controlled pharmaceutical storage room with stainless steel shelving and a ceiling-mounted refrigeration unit
More than 85% of biologics need temperature-controlled handling, and cold chain breakdowns cost an estimated $35 billion a year.

Temperature failures spoil billions of dollars in vital biopharmaceuticals and vaccines annually, forcing a shift toward real-time telemetry.

  • The global cold chain logistics market size is expected to reach 361.37 billion U.S. dollars in 2025. (Mordor Intelligence 2026[14])
  • The global cold chain logistics market is forecasted to reach 515.79 billion U.S. dollars by 2031. (Mordor Intelligence 2026[14])
  • The global cold chain logistics market is projected to grow at a compound annual growth rate of 6.12 percent from 2026 to 2031. (Mordor Intelligence 2026[14])
  • The global cold chain logistics market is estimated to reach 941.9 billion U.S. dollars by 2034. (IMARC Group 2025[10])
  • The global cold chain logistics market is projected to exhibit a compound annual growth rate of 12.44 percent from 2026 to 2034. (IMARC Group 2025[10])
  • North America dominated the cold chain logistics market in 2025 with a 38.6 percent market share. (IMARC Group 2025[10])
  • Refrigerated warehouses hold the largest share of the cold chain logistics market at approximately 65.0 percent. (IMARC Group 2025[10])
  • The United States holds an 87.30 percent share of the regional cold chain logistics market. (IMARC Group 2025[10])
  • More than 85% of biologics require temperature-controlled manufacturing, storage, and distribution. (Supply Chain Management Review[4])
  • An estimated 40-60% of all pharmaceuticals require temperature-controlled logistics to maintain their safety and efficacy during transport and storage. (Envirotainer[6])
  • An estimated $35 billion is lost annually due to global pharmaceutical cold chain breakdowns. (Envirotainer[6])
  • Vaccine spoilage due to thermal excursions represents an annual 35 billion U.S. dollar loss to drug makers. (Mordor Intelligence 2026[14])
  • Up to 50% of vaccines are compromised each year due to failures in temperature control and logistics. (World Health Organization[6])
  • Significant temperature excursions during transport damage or expose 20% of all temperature-sensitive pharmaceuticals. (EROAD[15])
  • Cold chain logistics issues are to blame for 30% of the temperature-sensitive pharmaceuticals that must be disposed of. (EROAD[15])
  • Approximately 12% of pharmaceutical shipments still experience temperature excursions during transit and storage. (Envirotainer[6])
  • Early adopters of IoT-enabled telematics report product-loss reductions of up to 30 percent. (Mordor Intelligence 2026[14])
  • Global ultra-low storage capacity has increased by 200 percent since 2020. (WHO 2026[14])

Global Sourcing and Active Ingredient Statistics

Interior of a pharmaceutical process plant, with a stainless steel reactor vessel below dense overhead pipework
China produced 45% of active pharmaceutical ingredients by 2024 and India 43%, while the US share fell to 3%.

With the U.S. relying on foreign nations for 75% of essential drugs, proposed pharmaceutical tariffs present severe supply risks.

  • The United States relies on foreign nations for 75 percent of its essential drug supply. (Senate Special Committee on Aging[2])
  • China supplies upwards of 80 percent of active pharmaceutical ingredients in generic drugs for the United States. (Senate Special Committee on Aging[2])
  • There were 2,385 FDA-registered sites globally whose registered operations include active pharmaceutical ingredient manufacture as of August 2026. (PharmaTek Intelligence 2026[16])
  • India, the US, and China together hold 65% of every active pharmaceutical ingredient manufacturing site registered with the FDA as of August 2026. (PharmaTek Intelligence 2026[16])
  • India accounts for 540 FDA-registered active pharmaceutical ingredient manufacturing sites as of August 2026. (PharmaTek Intelligence 2026[16])
  • The United States is home to 508 FDA-registered active pharmaceutical ingredient manufacturing sites as of August 2026. (PharmaTek Intelligence 2026[16])
  • China accounts for 493 FDA-registered active pharmaceutical ingredient manufacturing sites as of August 2026. (PharmaTek Intelligence 2026[16])
  • The United States accounts for 21% of FDA-registered active pharmaceutical ingredient manufacturing sites as of 2026. (LGM Pharma 2026[17])
  • Only 486 of the 2,385 FDA-registered active pharmaceutical ingredient manufacturing sites carry a matching GMP certificate in the EU or UK registers as of August 2026. (PharmaTek Intelligence 2026[16])
  • China produced 45 percent of active pharmaceutical ingredients by 2024. (U.S. Pharmacopeia 2024[18])
  • India produced 43 percent of active pharmaceutical ingredients by 2024. (U.S. Pharmacopeia 2024[18])
  • Europe’s share of active pharmaceutical ingredients fell to 6 percent by 2024. (U.S. Pharmacopeia 2024[18])
  • The United States’ share of active pharmaceutical ingredients fell to 3 percent by 2024. (U.S. Pharmacopeia 2024[18])
  • Nearly 41 percent of key starting materials used in U.S.-approved active pharmaceutical ingredients are produced only in China. (U.S. Pharmacopeia 2026[18])
  • Across all medications, 16 percent of key starting materials used in U.S.-approved active pharmaceutical ingredients are produced only in India. (U.S. Pharmacopeia 2026[18])
  • China sole-sources key starting materials for 100 percent of active pharmaceutical ingredients for angiotensin II receptor blockers. (ITIF 2026[18])
  • China controls key starting materials for 94 percent of amoxicillin. (ITIF 2026[18])
  • China controls key starting materials for 83 percent of direct acting antivirals. (ITIF 2026[18])
  • Active pharmaceutical ingredient manufacturing costs are about 30 to 35 percent lower in India than in the United States. (IQVIA 2026[18])
  • Active pharmaceutical ingredient manufacturing costs are about 35 to 40 percent lower in China than in the United States. (IQVIA 2026[18])

Digital Supply Chain and AI Integration Statistics

Pharmaceutical manufacturers are adopting AI-enabled planning platforms to automate forecasting and resolve capacity constraints.

  • The AI-enabled pharma supply chain market was valued at USD 1.06 billion in 2025. (Mordor Intelligence 2025[19])
  • The AI-enabled pharma supply chain market reached USD 1.21 billion in 2026. (Mordor Intelligence 2026[19])
  • The AI-enabled pharma supply chain market is projected to reach USD 2.30 billion by 2031. (Mordor Intelligence 2026[19])
  • The AI-enabled pharma supply chain market is projected to register a CAGR of 13.82% from 2026 to 2031. (Mordor Intelligence 2026[19])
  • The software component dominated the AI-enabled pharma supply chain market with a 63.45% share in 2025. (Mordor Intelligence 2025[19])
  • Cloud solutions dominated the AI-enabled pharma supply chain market in 2025, securing a 68.31% share. (Mordor Intelligence 2025[19])
  • Pharmaceutical manufacturers accounted for a 56.79% revenue share of the AI-enabled pharma supply chain market in 2025. (Mordor Intelligence 2025[19])
  • Demand forecasting and planning accounted for a 32.48% share of the AI-enabled pharma supply chain market in 2025. (Mordor Intelligence 2025[19])
  • The global digital pharmaceutical supply chain management market was valued at USD 1.26 Billion in 2025. (InsightAce Analytic 2025[20])
  • The global digital pharmaceutical supply chain management market is projected to reach USD 2.76 Billion by 2035. (InsightAce Analytic 2026[20])
  • The digital pharmaceutical supply chain management market is predicted to grow at an 8.3% CAGR from 2026 to 2035. (InsightAce Analytic 2026[20])
  • Platforms and AI models in the pharma supply chain market are projected to grow at a 14.71% CAGR through 2031. (Mordor Intelligence 2026[19])
  • On-premise rollouts in the AI-enabled pharma supply chain market are projected to grow at a 16.38% CAGR. (Mordor Intelligence 2026[19])
  • Contract manufacturing organizations are expected to grow at an 18.43% CAGR in the AI-enabled pharma supply chain market through 2031. (Mordor Intelligence 2026[19])
  • The Asia-Pacific region is expected to register the highest CAGR of 18.25% in the AI-enabled pharma supply chain market through 2031. (Mordor Intelligence 2026[19])
  • North America dominated the AI-enabled pharma supply chain market with a 38.51% share in 2025. (Mordor Intelligence 2025[19])
  • A 2026 survey found that 68% of executives view integration as the primary barrier to AI platform rollouts. (TraceLink 2026[19])
  • Only 20% of commercial AI tools currently comply with EU GMP prospective validation and bias testing mandates. (European Commission 2024[19])
  • The software category held the largest market share of 39.7% in the digital pharmaceutical supply chain management market in 2022. (InsightAce Analytic 2022[20])

Supply Chain Environmental Impact Statistics

Cargo ships berthed alongside a refinery, smoke rising from a stack into a grey sky
Supply chains account for about 75% of emissions at public biotech and pharma companies, and 88% at private ones.

Supply chain operations account for up to 88% of total emissions for biotech and pharmaceutical companies.

  • Supply chains account for about 75% of emissions for public biotech and pharma companies in 2025. (My Green Lab 2025[5])
  • Supply chains account for 88% of emissions for private biotech and pharma companies in 2025. (My Green Lab 2025[5])
  • The pharmaceutical industry’s emission intensity is approximately 55% higher than that of the automotive industry. (Datwyler 2022[21])
  • Health systems produce 4-5% of national greenhouse gas emissions. (Booth et al. 2023[22])
  • The contribution of pharmaceuticals to national health systems greenhouse gas emissions ranges from 10-55%. (Booth et al. 2023[22])
  • In 2019, medicines and chemicals were responsible for 20% of the carbon footprint of the UK National Health Service. (Booth et al. 2023[22])
  • Once supply chains are included, the implied temperature of the biotech and pharma sector’s emissions rises to 1.9°C in 2025. (My Green Lab 2025[5])
  • Among biotech and pharma companies with the highest-quality disclosures, 52% have medium-term Scope 1-2 targets aligned with a 1.5°C pathway in 2025. (My Green Lab 2025[5])
  • The largest biotech and pharma companies cut their Scope 3 supply chain emissions intensity by about 5% in 2025. (My Green Lab 2025[5])
  • Shipping 1 kg of snake antivenom ampoules from a manufacturer in India to a South African hospital emits 207.78 kg CO2e. (Ashworth et al. 2025[13])
  • Shipping 1 kg of antiretroviral pills from a manufacturer in India to a hospital in South Africa emits 0.88 kg CO2e. (Ashworth et al. 2025[13])
  • Anesthetic gases and inhalers accounted for an additional 5% of the UK National Health Service carbon footprint in 2019. (Booth et al. 2023[22])
  • Datwyler doubled its renewable electricity usage to 38% of total consumption. (Datwyler 2022[21])
  • Datwyler reduced its CO2 emissions per revenue unit by 8.1% annually for four consecutive years. (Datwyler 2022[21])
  • Datwyler achieved a waste recycling rate of 74.1% in its manufacturing operations. (Datwyler 2022[21])

Serialization, Compliance, and Security Statistics

Warehouse worker in a hard hat and high-visibility vest scanning a barcode label on a palletised carton
Wholesale distributors reported transaction data accuracy above 98% ahead of the August 2025 DSCSA enforcement deadline.

Strict DSCSA enforcement has improved data accuracy, yet data errors and rising cargo theft threaten supply security.

  • Wholesale distributors reported transaction data accuracy exceeding 98% leading up to the August 2025 DSCSA enforcement deadline. (Healthcare Distribution Alliance 2025[8])
  • In September 2025, 94% of surveyed drug manufacturers stated they were routinely providing complete serialized data for their products to the vast majority of their customers. (Partnership for DSCSA Governance 2025[23])
  • In June 2024, 58% of drug manufacturers surveyed stated they routinely provided complete serialized data for products to the vast majority of their customers. (Partnership for DSCSA Governance 2024[23])
  • Only 72% of pharmacy respondents surveyed in September 2025 reported receiving transaction information from their trading partners. (Partnership for DSCSA Governance 2025[23])
  • Wholesalers reported that 2% of all pharmaceutical products received still had a serialization data problem. (Wholesalers 2025[24])
  • A study in a UK hospital trust found that scanning serialized medicines yielded a combined operational detection rate of 81.4% for expired, recalled, and fake drugs during its first stage. (Naughton et al. 2016[25])
  • Pharmaceutical cargo theft incidents experienced a 136% increase in North America in 2025. (Safe and Sound 2025[26])
  • Pharmaceuticals accounted for 6% of all cargo theft incidents in North America in 2025. (Safe and Sound 2025[26])

Counterfeit and Substandard Medicine Statistics

Counterfeit drugs drain up to $431 billion annually from the global economy and threaten patient safety.

  • The global trade in counterfeit pharmaceuticals is estimated to be worth between $200 billion and $431 billion annually. (World Health Organization 2017[3])
  • Up to 10% of medicines available globally could be counterfeit. (World Health Organization 2017[3])
  • The United States biopharmaceutical industry loses between $37.6 billion and $162.1 billion in annual revenues due to counterfeit drugs. (Pacific Research Institute 2020[7])
  • Lost revenues from counterfeit drugs reduce the total economic output of the United States by between $82.0 billion and $353.3 billion. (Pacific Research Institute 2020[7])
  • Counterfeit pharmaceuticals have reduced the total number of jobs in the United States by between 57,500 and 247,800. (Pacific Research Institute 2020[7])
  • Lost economic output from counterfeit medicines denies federal and state governments tax revenues of between $4.5 billion and $19.5 billion. (Pacific Research Institute 2020[7])
  • Counterfeit drugs contribute to an estimated $75 billion annual loss to the global economy from increased healthcare costs and lost income. (NABP 2020[3])
  • A staggering 96% of online pharmacies operate without complying with pharmacy safety and standards. (PharmOut[27])
  • Over 50% of medicines purchased from online pharmacies are estimated to be counterfeit by the World Health Organization. (World Health Organization[7])
  • FDA inspections of suspicious mail packages at international mail facilities revealed that as much as 87 percent contained illegal, unapproved, counterfeit, or dangerous drugs. (Food and Drug Administration 2019[7])
  • An analysis of drug samples in low- and middle-income countries revealed that 13.6% of essential medicines were of poor quality. (Ozawa et al. 2018[28])
  • Between 10% to 70% of internally distributed medications in low-income nations are counterfeit, contaminated, or substandard. (PharmOut[27])
  • A study of essential medicines in low- and middle-income countries found that 19.1% of antimalarials were substandard or falsified. (Ozawa et al. 2018[28])
  • A study of essential medicines in low- and middle-income countries found that 12.4% of antibiotics were substandard or falsified. (Ozawa et al. 2018[28])
  • In a global study of counterfeit drugs in legitimate supply chains, China was identified as the source country in 27.6% of reported incidents. (Mackey et al. 2015[29])
  • An analysis of counterfeit drug incidents showed that anti-infectives were the most common drug class, accounting for 21.1% of reports. (Mackey et al. 2015[29])
  • A quality analysis of ciprofloxacin samples from over-the-counter drug stores in Nigeria showed that 26.9% failed to reach even eighty percent of their declared active content. (Thu et al. 2025[30])
  • Counterfeit drugs make up less than 1% of those sold in United States brick and mortar pharmacies. (Centers for Disease Control[7])
  • More than 80 cases have been opened involving GLP-1 and Botox products, emphasizing risks in unregulated settings like med spas. (Two Labs 2025[24])
  • Machine learning models designed to identify counterfeit medicines and contaminated food achieved a validation accuracy of greater than 90%. (Mishra et al. 2019[31])

Drug Shortage Prevalence and Regulatory Statistics

Hands placing a notice on an empty pharmacy shelf, with sparse stock on the shelves around it
Active US drug shortages peaked at 323 in the first quarter of 2024, and the FDA attributes more than 60% of them to manufacturing quality problems.

Manufacturers are utilizing advanced planning tools to prevent drug stockouts as active shortages reach historic highs.

  • Active drug shortages in the United States reached an all-time high of 323 in the first quarter of 2024. (ASHP 2024[1])
  • The number of active national drug shortages in the United States was 227 as of the second quarter of 2026. (University of Utah 2026[32])
  • The number of active drug shortages stood at 216 in the fourth quarter of 2025. (ASHP and University of Utah[33])
  • There were 270 drugs in shortage in March 2025, with chemotherapy agents representing approximately 8% of the total. (FDA 2025[9])
  • A total of 89 new drug shortages were identified during 2025, representing the lowest annual count since 2006. (ASHP and University of Utah[33])
  • During calendar year 2025, the FDA’s CDER and CBER worked with manufacturers to successfully prevent 330 drug shortages. (FDA 2025[34])
  • The FDA helped prevent 283 drug shortages in calendar year 2024. (FDA 2024[34])
  • The FDA helped prevent 236 drug shortages in calendar year 2023. (FDA 2023[34])
  • Sole-source products manufactured by a single supplier accounted for 48% of all new drug shortages in 2026. (University of Utah 2026[32])
  • The FDA attributes more than 60% of drug shortages to manufacturing quality problems. (FDA 2025[9])
  • The reasons for drug shortages remain unidentified in 18% of cases reported to the FDA. (FDA 2025[9])
  • Data shows that 50% of active drug shortages in the United States persist for two or more years. (ASHP[1])
  • Seventy-five percent of all active drug shortages in late 2025 started in 2022 or later. (ASHP and University of Utah[33])
  • An analysis of drug shortages between 2018 and 2023 showed that there were 1,391 generic drug shortage events compared to 600 brand shortage events. (HHS ASPE 2023[1])
  • The FDA has sent 11 non-compliance letters to firms failing to notify the agency of shortages since 2014. (FDA 2025[34])

Healthcare Provider and Patient Impact Statistics

Patient resting in a hospital bed with an intravenous cannula taped to the back of the hand
In a 2023 survey, 99% of hospital pharmacists reported experiencing drug shortages.

Oncology clinics and hospitals face severe treatment delays and millions in added labor costs due to active drug shortages.

  • In a 2023 survey, 99% of hospital pharmacists reported experiencing drug shortages. (ASHP 2023[1])
  • A survey of NCCN member institutions in mid-2023 showed that 89% of them had experienced a shortage of at least one drug. (NCCN 2023[35])
  • Nearly 54% of National Cancer Institute Community Oncology Research Program practices were seriously affected by drug shortages in the 3 months prior to survey completion. (JCO Oncology Practice 2026[36])
  • Of 93 US community oncology practices surveyed, 52.7% reported that cancer care delivery was seriously affected by a drug shortage in the past 3 months. (JCO Oncology Practice 2025[37])
  • During a 2023 survey, 32% of hospital pharmacists characterized the drug shortage situation as critical, requiring active rationing or treatment delays. (ASHP 2023[1])
  • Carboplatin was in short supply at 93% of surveyed National Comprehensive Cancer Network institutions during a survey in May 2023. (National Comprehensive Cancer Network 2023[38])
  • Cisplatin was in short supply at 70% of surveyed National Comprehensive Cancer Network institutions during a survey in May 2023. (National Comprehensive Cancer Network 2023[38])
  • A survey of cancer centers in May 2023 found that 67% of institutions experienced a shortage of methotrexate. (National Comprehensive Cancer Network 2023[39])
  • A survey of cancer centers in May 2023 found that 26% of institutions experienced a shortage of 5-fluorouracil (5FU). (National Comprehensive Cancer Network 2023[39])
  • A survey of cancer centers in May 2023 found that 19% of institutions experienced a shortage of paclitaxel. (National Comprehensive Cancer Network 2023[39])
  • Only 64% of surveyed cancer centers were able to give carboplatin to all patients who needed it during the May 2023 shortage. (National Comprehensive Cancer Network 2023[38])
  • Twenty percent of surveyed cancer centers reported they were able to continue giving carboplatin to only some patients during the drug shortage in May 2023. (National Comprehensive Cancer Network 2023[38])
  • An ethical dilemma related to a drug shortage was experienced by 50.5% of surveyed NCORP community oncology practices. (JCO Oncology Practice 2026[36])
  • To address drug shortages, 91.5% of surveyed NCORP community oncology practices reported using alternative drugs. (JCO Oncology Practice 2026[36])
  • Stockpiling was reported by 87.2% of surveyed NCORP community oncology practices as a strategy to address drug shortages. (JCO Oncology Practice 2026[36])
  • Action plan development was a strategy used by 84.0% of surveyed NCORP community oncology practices to address drug shortages. (JCO Oncology Practice 2026[36])
  • A substantial resource expenditure was reported by 70.8% of oncology practices where cancer care delivery was seriously affected by drug shortages. (JCO Oncology Practice 2025[37])
  • An analysis estimated that the annual labor cost of drug shortages to hospitals in the United States is $359 million. (ASHP[1])
  • The estimated annual labor cost of Japanese hospital pharmacists required to deal with drug shortages was 7.1 billion JPY based on a 2024 survey. (Japan Municipal Hospital Association 2024[40])
  • A survey conducted in 2024 found that 98.1% of hospital pharmacy directors reported recent drug shortages negatively affected other practices of the pharmacy. (Japan Municipal Hospital Association 2024[40])

Frequently Asked Questions

What is the financial impact of pharmaceutical cold chain failures?

Cold chain breakdowns cost the global pharmaceutical industry $35 billion annually. Failures in temperature control compromise up to 50% of vaccines each year, leading to massive product waste.

How dependent is the United States on foreign sourcing for active drug ingredients?

The United States imports 75% of its essential drug supply. China produces over 80% of the active pharmaceutical ingredients (APIs) used in U.S. generic drugs and controls 45% of the global API market.

What role does artificial intelligence play in the modern pharmaceutical supply chain?

Artificial intelligence automates demand forecasting and production planning. The AI-enabled pharma supply chain market reached $1.21 billion in 2026 and is growing at a 13.82% annual rate.

What is the scale and economic impact of counterfeit pharmaceuticals?

Counterfeit drug trade generates up to $431 billion annually, accounting for up to 10% of global medicines. This illicit market costs the U.S. biopharmaceutical industry up to $162.1 billion in lost revenue each year.

How severe are drug shortages and what causes them?

Active U.S. drug shortages hit a record high of 323 in early 2024. The FDA attributes over 60% of these shortages to manufacturing quality issues, worsened by a high reliance on single-source suppliers.

Methodology

We compiled 143 distinct statistics from 40 sources: 30 industry reports, market analyses, government filings and trade surveys, 9 peer-reviewed papers (via PubMed Central, ASCO Publications and the Journal of Transport and Supply Chain Management) and 1 arXiv preprint. Ten headline figures appear twice, once in the summary at the top of the page and again in their thematic section, giving 153 entries in total. Each figure was checked against the source it links to, and where a report quoted another organisation’s data we linked to the original wherever we could read it. Last updated 18 September 2026.

Cite These Statistics

You are welcome to use any statistic on this page. Please credit plaio.com and link back to this page as the source.

References

  1. “The Hidden Architecture of Drug Shortages: Why Inventory Economics Determine Patient Access.” Pharmaceutical Commerce. https://www.pharmaceuticalcommerce.com/view/why-inventory-economics-determine-patient-access
  2. “Senate Aging Committee Examines Foreign Drug Supply Threats.” Legis1. https://legis1.com/news/pharmaceutical-supply-chain-senate-hearing
  3. “The Economic Impact of Counterfeit Healthcare Products.” TrueMed, 8 August 2024. https://truemedinc.com/blog/the-economic-impact-of-counterfeit-healthcare-products/#:~:text=The%20Scope%20of%20the%20Problem,substantial%20threat%20to%20public%20health.
  4. “Cold Chain Management: A Comprehensive Guide.” PharmaSource. https://pharmasource.global/content/guides/category-guide/cold-chain-management-a-comprehensive-guide/
  5. “Carbon Impact Report: Biotech & Pharma Industry Analysis.” My Green Lab, 2025. https://mygreenlab.org/resources/carbon-impact-reports/
  6. “What Happens When the Cold Chain Breaks?” European Pharmaceutical Manufacturer. https://pharmaceuticalmanufacturer.media/pharmaceutical-industry-insights/pharmaceutical-logistics-distribution/what-happens-when-the-cold-chain-breaks/
  7. “RAI Explainer: How Counterfeit Drugs Threaten U.S. Health and Innovation.” Center for Strategic and International Studies (CSIS). https://www.csis.org/blogs/perspectives-innovation/rai-explainer-how-counterfeit-drugs-threaten-us-health-and-innovation
  8. “DSCSA Compliance: Milestones, More Deadlines — and the Road Ahead.” Pharmaceutical Commerce. https://www.pharmaceuticalcommerce.com/view/dscsa-compliance-milestones-more-deadlines-and-the-road-ahead
  9. “Key Drivers and Mitigation Strategies of Oncology Drug Shortages 2023 to 2025.” The Cancer Journal, September–October 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12459136/
  10. “Cold Chain Logistics Market Size, Share & Forecast 2034.” IMARC Group, 2025. https://www.imarcgroup.com/cold-chain-logistics-market
  11. “Healthcare Supply Chain Management Market Trends 2035.” Market Research Future. https://www.marketresearchfuture.com/reports/healthcare-supply-chain-management-market-5716
  12. “Global Pharmaceutical Supply Chain Management Market Share.” Inkwood Research. https://www.inkwoodresearch.com/reports/pharmaceutical-supply-chain-management-market/#:~:text=FAQs,was%20valued%20at%20%242302.87%20million.
  13. “Emissions in Pharmaceutical Distribution: A Systematic Literature Review of Accounting Methodologies in Supply Chains.” Journal of Transport and Supply Chain Management, 2023. https://jtscm.co.za/index.php/jtscm/article/view/1150/1956
  14. “Cold Chain Logistics Market Size & Growth Outlook 2031.” Mordor Intelligence. https://www.mordorintelligence.com/industry-reports/cold-chain-logistics-market
  15. “The Cost of Temperature Excursions in the Pharmaceutical Industry.” EROAD. https://www.eroad.com/blog-and-news/the-cost-of-temperature-excursions-in-the-pharmaceutical-industry
  16. “Where the World's APIs Are Actually Made: 2,385 FDA-Registered Sites.” PharmaTek Intelligence, August 2026. https://pharmatek.co.uk/reports/api-manufacturing-geography
  17. “Tariff Pressure on APIs in 2026.” LGM Pharma, 2026. https://lgmpharma.com/blog/tariff-pressure-apis-2026/
  18. “How America Can Reduce Its Dependence on Chinese Active Pharmaceutical Ingredients (APIs).” Information Technology and Innovation Foundation (ITIF), 31 August 2026. https://itif.org/publications/2026/08/31/how-america-reduce-dependence-chinese-active-pharmaceutical-ingredients-apis/
  19. “AI-Enabled Pharma Supply Chain Market Size, Share & 2031 Growth Trends Report.” Mordor Intelligence. https://www.mordorintelligence.com/industry-reports/ai-enabled-pharma-supply-chain-market
  20. “Digital Pharmaceutical Supply Chain Management Market Size, Trends and Forecast 2026 to 2035.” InsightAce Analytic. https://www.insightaceanalytic.com/report/digital-pharmaceutical-supply-chain-management-market-/1911
  21. “ESG in Pharma: Sustainability Strategy for Pharmaceutical Packaging.” Datwyler. https://healthcare.datwyler.com/resources/esg-in-pharma-sustainability-strategy
  22. “Pharmaceutical Company Targets and Strategies to Address Climate Change: Content Analysis of Public Reports from 20 Pharmaceutical Companies.” International Journal of Environmental Research and Public Health, 11 February 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC9967855/
  23. “FDA DSCSA Public Meeting Highlights Interdependence of Trading Partners.” Healthcare Leadership Council, 3 October 2025. https://www.hlc.com/en/publications/fda-dscsa-public-meeting-highlights-interdependence-of-trading-partners
  24. “Navigating the Future of Pharmaceutical Traceability: Insights from the 2025 HDA Conference.” Two Labs, 2025. https://twolabs.com/navigating-the-future-of-pharmaceutical-traceability-insights-from-the-2025-hda-conference/
  25. “Effectiveness of Medicines Authentication Technology to Detect Counterfeit, Recalled and Expired Medicines: A Two-Stage Quantitative Secondary Care Study.” BMJ Open, 9 December 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC5168655/
  26. “Cargo Theft Statistics.” Safe and Sound Security, 2025. https://getsafeandsound.com/blog/cargo-theft-statistics/
  27. “The Impact of Counterfeit Medications: Global Statistics and Risks.” PharmOut, 3 July 2019. https://www.pharmout.net/counterfeit-medications-global-statistics/
  28. “Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.” JAMA Network Open, 3 August 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6324280/
  29. “Counterfeit Drug Penetration into Global Legitimate Medicine Supply Chains: A Global Assessment.” The American Journal of Tropical Medicine and Hygiene, June 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4455087/
  30. “Investigation of CIP Quality in Over-the-Counter Drug Stores of Resource-Limited Countries: A Comparative Study in Vietnam and Nigeria.” JAC-Antimicrobial Resistance, April 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11920618/
  31. “Low-Cost Spectrogram Based Counterfeit Medicine Detection.” arXiv, 10 April 2019. arXiv:1904.07152. https://arxiv.org/abs/1904.07152
  32. “Drug Shortages Statistics.” ASHP / University of Utah Drug Information Service. https://www.ashp.org/drug-shortages/shortage-resources/drug-shortages-statistics?loginreturnUrl=SSOCheckOnly
  33. “Drug Shortages: ASHP Report 2025 Decline.” Pharmacy Practice News, February 2026. https://www.pharmacypracticenews.com/Online-First/Article/02-26/Drug-Shortages-ASHP-Report-2025-Decline/79741
  34. “CY 2025 Drug Shortages Report to Congress.” U.S. Food and Drug Administration, 2025. https://www.fda.gov/media/193637/download
  35. “Drug Shortages Threaten Cancer Care.” Pulmonology Advisor. https://www.pulmonologyadvisor.com/features/drug-shortages-threaten-cancer-care/
  36. “Impact of Drug Shortages on Cancer Care Delivery Within the National Cancer Institute Community Oncology Research Program.” JCO Oncology Practice, May 2026. doi:10.1200/OP-25-00057. https://ascopubs.org/doi/10.1200/OP-25-00057
  37. “Drug Shortages Have Serious Impacts on Cancer Care at Community Practices.” Cancer Therapy Advisor. https://www.cancertherapyadvisor.com/news/drug-shortages-have-serious-impacts-on-cancer-care-at-community-practices/
  38. “Chemotherapy Shortage: More Than 90% of Cancer Centers Affected.” Cancer Therapy Advisor. https://www.cancertherapyadvisor.com/news/chemotherapy-shortage-cancer-centers-more-than-90-affected/
  39. “NCCN Drug Shortage Survey.” National Comprehensive Cancer Network, 2023. https://www.nccn.org/docs/default-source/oncology-policy-program/NCCN-Drug-Shortage-Survey.pdf
  40. “Impact of Drug Shortages on the Work of Hospital Pharmacists in Japan.” Journal of Pharmaceutical Policy and Practice, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12777919/

For supply chain consultancies

Are you a supply chain consultancy with pharma clients?

Contact UsExplore Supply Planning

Start smarter planning faster with PLAIO

Made for pharma supply chains by pharma supply chain experts

Book a Demo

Cookie settings

To enhance your experience on our site and to analyze traffic, we use cookies. By clicking "Accept All," you agree to the storing of cookies on your device for analytics purposes. You can manage your settings or learn more in our Privacy Policy.

Manage Settings

    • Your Privacy Matters to Us

    We use cookies to improve your browsing experience and analyze how our website is used. These cookies allow us to understand trends, monitor website traffic, and gather insights to make the site better for you.

    We respect your privacy and are committed to transparent data usage.

    Why Do We Use Cookies?

    Necessary Cookies: These ensure that the website functions properly.

    Analytics Cookies: These help us track site traffic, user behavior, and performance metrics. The data collected is anonymous and allows us to continuously optimize the site.

    Preferences Cookies: We may use cookies to remember your preferences and tailor your experience.

    Marketing Cookies: We may use cookies for marketing purposes.

    Your Control, Your Choice

    By clicking "Accept All," you consent to the use of all cookies. If you prefer, you can customize your choices and opt out of certain cookies. You can learn more about how we handle data and cookies in our Privacy Policy.